We are heading into ASH and that is sure to be the topic of much discussion but I find it more and more difficult to trade these medical conferences as.
Trading is slow this week but news is not. Yesterday was better but I still think it is too early to call the sector back but at the very least.
The sector still cannot gain real footing and follow positive days with additional positive days. That being said as long as the positive days either outnumber or have higher gains.
It has been a tough couple of days with pretty broad weakness but we will see how we end the week as many stocks have had a decent run so.
Loxo Oncology presented highly anticipated results from its ongoing Phase 1 study of TRK inhibitor LOXO-101 yesterday November 8, in a latebreaker at AACR-NCI-EORTC; they did not disappoint. Disclosure of.
Despite some additional M&A news the sector is off to a weak start. I suspect this eventually reverses today but would also take it as a strong signal if we.
We finally get a merger Monday of sorts although only one of the deals is a public company. It will be telling to a certain extent how the SMIDs respond.
The Bull/Bear tussle in Sarepta has been ongoing for years now. Long term investors have ridden a rollercoaster as excitement has inevitably been followed by disappointment. Its Exon 51 skipping.
Global Blood Therapeutics (GBT) is a recent graduate of Third Rock Ventures, a highly regarded firm with a list of innovative portfolio companies including Bluebird Bio, Foundation Medicine, Agios, and.
As I noted before, it appears that the sector is improving and while I would not say it has turned, I would argue that the odds are better that the.
I really thought the week would start with more of a bang but it seems much more like a whimper. Sure we had more VRX news/speculation but we really did.
Unfortunately, the discussion for the sector continues to revolve around specialty pharma. This has brought the sector down (although perhaps not down as far as we would have thought, so.
The sector continues to be under pressure, although we seem to be staying above the recent lows which remains critical. We are entering earnings season and it will be interesting.
Some interesting news that I want to focus on today. It seems that sentiment is finally starting to turn as the sector is rallying even though we have some less.
Raptor Pharmaceuticals is a small Novato, CA. company that markets Procysbi for the treatment of nephropathic cystinosis. It has active clinical trials in Huntington’s Disease and Leigh Syndrome. A recent.
I am not sure if the sector sold off yesterday as simply a normal short term move or whether there were real concerns about the democratic debate. I suspect a.
I would say after yesterday that the sector looks a little better but I think more to the point it seems that volatility is the best word that describes the.
Today is going to be a nice tell for the sector. We essentially have a positive market backdrop but more importantly competing headlines. There is the continued pricing discussion highlighted.
This is a brief analysis of recent entrectinib data presented by Ignyta. Entrectinib is a multi-kinase inhibitor with potent activity against TrkA/B/C, ROS1, and ALK. It was licensed from Nerviano.
This week BioMarin (BMRN) announced it won the first DMD patent battle against Sarepta (SRPT) in a press release stating, “BioMarin Receives Favorable Ruling in the Use of Exon.